Generic Name and Formulations:
Nitroglycerin 0.1mg/hr, 0.2mg/hr, 0.4mg/hr, 0.6mg/hr; transdermal patches.
Medicis Pharmaceuticals Corp
Indications for MINITRAN:
Prophylaxis of angina. Not for acute attacks.
Initially one 0.2mg/hr or 0.4mg/hr patch for 12–14hrs/day. Remove patch for 10–12hrs/day.
Acute or recent MI. Volume depletion. Hypotension. Heart failure. Hypertrophic cardiomyopathy. Reduce dose or discontinue if hypotension occurs. Remove before defibrillation or cardioversion. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, dizziness, flushing, hypotension, increased angina, tachycardia, faintness, nausea, vomiting, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML